Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine by Kazuya Sato, Nodoka Tsukada, Junki Inamura, Shigetsuna Komatsu, Keisuke Sato, Masayo Yamamoto, Motohiro Shindo, Kentaro Moriichi, Yusuke Mizukami, Mikihiro Fujiya, Yoshihiro Torimoto, Toshikatsu Okumura

“…Treatment with reduced-dose AZA should be considered as a therapeutic option for MS in elderly patients with MDS, especially patients who are ineligible for intensive chemotherapy.…”
Get full text

Identification of Immune-Related lncRNA Pairs and Construction and Validation of a New Prognostic Signature of Colon Cancer by Minxian Xu, Qing Li, Jianfang Zhang, Hui Xie

“…Then, the signature was evaluated by clinicopathological features, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. Results. We identified 8 lncRNA pairs including AC103740.1|LEF1-AS1, LINC02391|AC053503.5, WWC2-AS2|AL355916.2, AC104090.1|NEURL1-AS1, AC099524.1|AL161908.1, AC074011.1|AL078601.2, AL355916.2|LINC01723, and AP003392.4|LINC00598 from 71 differently expressed irlncRNAs. …”
Get full text

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases by Alexander Desuki, Frank Staib, Ines Gockel, Markus Moehler, Hauke Lang, Stefan Biesterfeld, Annett Maderer, Peter R. Galle, Martin R. Berger, Carl C. Schimanski

Get full text

Clinicopathological Features of 166 Cases of Invasive Ductal Breast Carcinoma and Effect of Primary Tumor Location on Prognosis after Modified Radical Mastectomy by Shiman Chen, Liang Yang, Yaqiong Li

“…There were no significant differences in age, menopause, histological grading, molecular typing, lymph node metastasis, vascular invasion, radiation therapy, and chemotherapy among different groups (P>0.05). Univariate analysis showed that molecular typing, lymph node metastasis, vascular invasion, and location of the primary tumor were all related to the prognosis of IDC patients after modified radical surgery, and the differences were statistically significant (P<0.05). …”
Get full text

Neoadjuvant Chemoradiotherapy Upregulates the Immunogenicity of Cold to Hot Tumors in Esophageal Cancer Patients by Yushi Nagaki, MD, PhD, Satoru Motoyama, MD, PhD, Yusuke Sato, MD, PhD, Akiyuki Wakita, MD, PhD, Hiromu Fujita, MD, PhD, Kohei Kemuriyama, MD, Ryohei Sasamori, MD, Shu Nozaki, MD, Kyoko Nomura, MD, PhD, Yoshihiro Minamiya, MD, PhD

“…In addition, several studies have suggested that chemotherapy and radiotherapy may convert cold tumors to hot tumors. …”
Get full text

Advances in Cell and Immune Therapies for Melanoma by Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigu, Ciprian Tomuleasa

“…Current clinical trials are exploring various combinations of immune checkpoint inhibitors with costimulatory receptor agonists, chemotherapy, targeted therapies, and other immunotherapies, with the goal of improving outcomes and reducing side effects for melanoma patients. …”
Get full text

Cardiac Tamponade as an Initial Manifestation of Cervical Cancer by Yuridia Evangelina Rodríguez-Rosales, Carlos Eduardo Salazar-Mejía, Blanca Angélica Soto-Martínez, David Hernández-Barajas, Oscar Vidal-Gutiérrez, Gabriela Sofia Gómez-Macías

“…Initial cytology of the pericardial fluid showed a poorly differentiated carcinoma, and a cervical biopsy revealed a squamous cell invasive carcinoma. Chemotherapy was started with carboplatin and paclitaxel, but no clinical improvement was noted and the patient died 46 days after arrival. …”
Get full text

PROTON RADIATION THERAPY: CLINICAL APPLICATION OPPORTUNITIES AND RESEARCH PROSPECTS by M. V. Zabelin, V. A. Klimanov, J. J. Galyautdinova, A. S. Samoilov, A. O. Lebedev, E. V. Shelyhina

“…There are data on extreme toxicity of a combination of a chemotherapy and photon radiation. It is supposed that physical properties of protons will allow to reduce toxicity of such technique, however clinical trials in comparison of protons and RTMI aren’t fi nished yet. …”
Get full text

Impact of HIF-1α, LOX and ITGA5 Synergistic Interaction in the Tumor Microenvironment on Colorectal Cancer Prognosis by Hayriye Tatlı Doğan, Mehmet Doğan, Seda Kahraman, Doğukan Çanakçı, Mehmet Ali Nahit Şendur, Mustafa Tahtacı, Fazlı Erdoğan

“…In addition, female gender; moderate to strong HIF-1α, LOX and ITGA5 stromal expression; and metastatic first line chemotherapy only were found to be independently associated with an increased risk of progression. …”
Get full text

The Role of Advanced Cardiac Imaging in Monitoring Cardiovascular Complications in Patients with Extracardiac Tumors: A Descriptive Review by Annamaria Tavernese, Valeria Cammalleri, Rocco Mollace, Giorgio Antonelli, Mariagrazia Piscione, Nino Cocco, Myriam Carpenito, Carmelo Dominici, Massimo Federici, Gian Paolo Ussia

“…Early detection of cardiac dysfunction, particularly due to cardiotoxicity from chemotherapy or radiotherapy, is essential to establish the disease’s overall prognostic impact. …”
Get full text

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study by Haiqing Zhao, Wei Zhang, Yuting Lu, Yin Dong, Zhihao He, Hongchao Zhen, Qin Li

“…Methods This single‐center, prospective, randomized, open‐label study was conducted, from January 2021 to December 2022, in Beijing Friendship Hospital, Capital Medical University, and participants were randomly assigned (1:1) to either the inosine (trial) or non‐inosine (control) group that received inosine (dosage: 0.2 g, three times/day) + PD‐1/PD‐L1 inhibitor or only PD‐1/PD‐L1 inhibitor ± targeted ± chemotherapy, respectively. Efficacy was assessed every 6 weeks (i.e., after every two–three treatment cycles). …”
Get full text

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma by Xueling Shi, Hongyu Zhao, Jiaqi Yu, Peng Cai, Shixiang Zhou, Ning Yang, Duojie Li

“…PD-1 expression in T lymphocyte subsets can predict short-term outcomes in patients and provide a theoretical basis for the sequential application of PD-1 immunosuppressants after radiotherapy and chemotherapy.…”
Get full text

Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3 by Liv Cathrine Heggebø, Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Ida Maria Henriksen Borgen, Hanne Blakstad, Hanne Blakstad, Cathrine Saxhaug, Pål André Rønning, Pitt Frederik Niehusmann, Katja Werlenius, Malin Blomstrand, Malin Blomstrand, Petter Brandal, Petter Brandal

“…Histological examination showed inflammatory changes without neoplastic tissue, albeit not very typical for postradiation changes. Adjuvant chemotherapy with temozolomide was continued.ConclusionThe presented case clearly shows that caution must be taken when interpreting cerebral MRI changes postradiation, and in particular after proton therapy. …”
Get full text

Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma by Małgorzata Banaszkiewicz, Jolanta Małyszko, Krzysztof Batko, Ewa Koc-Żórawska, Marcin Żórawski, Paulina Dumnicka, Artur Jurczyszyn, Karolina Woziwodzka, Joanna Tisończyk, Marcin Krzanowski, Jacek Małyszko, Anna Waszczuk-Gajda, Ryszard Drożdż, Marek Kuźniewski, Katarzyna Krzanowska

“…We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage, anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. …”
Get full text

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer by Maria Elena Lacruz, Saskia Thies, Andrea Schmidt-Pokrzywniak, Ian Wittenberg, Tobias Engler, Fabian Reinwald, Monika Klinkhammer-Schalke, Sylke Ruth Zeissig, Bianca Franke, Kerstin Weitmann, Atanas Ignatov

“…Pathological complete response (pCR) rates after neoadjuvant chemotherapy were highest in HER2-positive. HER2-low has higher hormone receptor positivity, distinguishing it from HER2-zero. …”
Get full text

Intrapericardial injection of hydrogels with ASC and their secretome to treat dilated cardiomyopathies by Tácia Tavares Aquinas Liguori, Gabriel Romero Liguori, Viktor Sinkunas, Cristiano Jesus Correia, Raphael dos Santos Coutinho e Silva, Fernando Luiz Zanoni, Vera Demarchi Aiello, Martin Conrad Harmsen, Luiz Felipe Pinho Moreira

“…Abstract Doxorubicin-induced cardiomyopathy (DOX-IC) is a significant and common complication in patients undergoing chemotherapy, leading to cardiac remodeling and reduced heart function. …”
Get full text

Prediction of Cisplatin‐Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information by Kaori Ambe, Yuka Aoki, Miho Murashima, Chiharu Wachino, Yuto Deki, Masaya Ieda, Masahiro Kondo, Yoko Furukawa‐Hibi, Kazunori Kimura, Takayuki Hamano, Masahiro Tohkin

“…This single‐center retrospective study included hospitalized patients aged ≥ 18 years who received the first course of cisplatin chemotherapy from January 1, 2011, to December 31, 2020, at Nagoya City University Hospital. …”
Get full text

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme by Noel J. Aherne, Linus C. Benjamin, Patrick J. Horsley, Thomaz Silva, Shea Wilcox, Julan Amalaseelan, Patrick Dwyer, Abdul M. R. Tahir, Jacques Hill, Andrew Last, Carmen Hansen, Craig S. McLachlan, Yvonne L. Lee, Michael J. McKay, Thomas P. Shakespeare

“…We correlated survival outcomes with patient functional status, extent of surgery, radiation dose, and use of chemotherapy. Results. Median survival for all patients was 11.3 months, with a median survival of 7.2 months for patients receiving 40.05 Gray (Gy) and a median survival of 17.4 months for patients receiving 60 Gy. …”
Get full text

Clinical treatment score Post-5 Years (CTS5) predicts the benefit of postmastectomy radiotherapy in patients with T1-2N1 luminal breast cancer by Ke Liu, Guan-Qiao Li, Si-Qi Li, Xue-Qin Chen, San-Gang Wu

“…Patients with younger age, T2 stage, higher tumor grade, a higher number of positive lymph nodes, infiltrating lobular carcinoma subtype, and receipt of chemotherapy were associated with the receipt of PMRT (all P < 0.05). …”
Get full text

A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews by France Ginchereau Sowell, Thom de Milliano, Keri J. S. Brady, Ginamarie Foglia, Medha Sasane, Samira Bensfia, Matthew Reaney

“…Symptoms were mostly attributed to systemic treatments (chemotherapy, immunotherapy and targeted therapy), followed by surgery. …”
Get full text